fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 26. More products

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Fluconazole

Form:

24 of 24 products shown

13 general benefit · 10 Limited Use · 1 not a benefit

Diflucan P.O.S. · DIN 02024152 · 10 mg/mL · oral liquid

Limited Use, Reason for Use code 528 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 528 required
Write on scriptReason for Use code 528 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 528
Reason for Use code 528 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Diflucan P.O.S. · DIN 02024152 Manufacturer: Pfizer Canada Inc.; listing date 1999-04-15 Health Canada: Marketed since 1995-12-31 · brand DIFLUCAN · ATC J02AC01 FLUCONAZOLE · form Powder for solution · route Oral · ingredients FLUCONAZOLE 50 MG/5ML · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Diflucan P.O.S.: Formulary list price $1.37 per unit (the source does not state the unit; exact figure $1.3654). What the ministry pays, not the patient.

Ministry pays: $1.3654 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02024152)

Source record
DIN 02024152: Diflucan P.O.S. Raw flags: sec12=Y, sec3=Y Item: 081204025; group id 8; item number 0010; lccId 00001; manufacturer id PFI Source form: O/L; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3654; ministry $1.3654 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02024152 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18010
Shortage status: resolved shortage (ended April 20, 2017); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02024152
Shortage record checked October 6, 2026

Act Fluconazole · DIN 02281260 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Act Fluconazole · DIN 02281260 Manufacturer: Actavis Pharma Company; listing date 2008-01-15 Daily cost (source): $2.5808 Health Canada: Marketed since 2020-04-16 · brand ACT FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Act Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02281260)

Source record
DIN 02281260: Act Fluconazole Raw flags: sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id ACV Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02281260 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76691
Interchangeable products
Apo-Fluconazole · DIN 02237370 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02517396 · $1.2904 Fluconazole · DIN 02534886 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: discontinued (December 20, 2024, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02281260
Shortage record checked October 6, 2026

Apo-Fluconazole · DIN 02237370 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Fluconazole · DIN 02237370 Manufacturer: Apotex Inc.; listing date 1999-09-15 Daily cost (source): $2.5808 Health Canada: Marketed since 2024-08-29 · brand APO-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237370)

Source record
DIN 02237370: Apo-Fluconazole Raw flags: sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237370 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60693
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02517396 · $1.2904 Fluconazole · DIN 02534886 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: shortage reported ended June 5, 2026 (report last updated June 5, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237370
Shortage record checked October 6, 2026

Fluconazole · DIN 02517396 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Fluconazole · DIN 02517396 Manufacturer: Sanis Health Inc.; listing date 2022-03-31 Daily cost (source): $2.5808 Health Canada: Marketed since 2022-01-14 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517396)

Source record
DIN 02517396: Fluconazole Raw flags: sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id SAI Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517396 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100680
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Apo-Fluconazole · DIN 02237370 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02534886 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517396
Shortage record checked October 6, 2026

Fluconazole · DIN 02534886 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Fluconazole · DIN 02534886 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-12-29 Daily cost (source): $2.5808 Health Canada: Marketed since 2023-10-24 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534886)

Source record
DIN 02534886: Fluconazole Raw flags: sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id SIV Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534886 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102377
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Apo-Fluconazole · DIN 02237370 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02517396 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534886
Shortage record checked October 6, 2026

Mylan-Fluconazole · DIN 02245292 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mylan-Fluconazole · DIN 02245292 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2003-04-16 Daily cost (source): $2.5808 Health Canada: Marketed since 2010-04-16 · brand MYLAN-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245292)

Source record
DIN 02245292: Mylan-Fluconazole Raw flags: sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id MYL Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245292 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69316
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Apo-Fluconazole · DIN 02237370 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02517396 · $1.2904 Fluconazole · DIN 02534886 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245292
Shortage record checked October 6, 2026

PMS-Fluconazole · DIN 02245643 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Fluconazole · DIN 02245643 Manufacturer: Pharmascience Inc.; listing date 2003-01-30 Daily cost (source): $2.5808 Health Canada: Marketed since 2002-06-05 · brand PMS-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245643)

Source record
DIN 02245643: PMS-Fluconazole Raw flags: sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245643 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69743
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Apo-Fluconazole · DIN 02237370 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02517396 · $1.2904 Fluconazole · DIN 02534886 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: active shortage (reported September 25, 2026, estimated to end November 10, 2026, last updated September 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245643
Shortage record checked October 6, 2026

Act Fluconazole · DIN 02281279 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Act Fluconazole · DIN 02281279 Manufacturer: Actavis Pharma Company; listing date 2008-01-15 Daily cost (source): $2.2891 Health Canada: Marketed since 2020-04-16 · brand ACT FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Act Fluconazole: Formulary list price $2.29 per unit (the source does not state the unit; exact figure $2.2891). What the ministry pays, not the patient.

Ministry pays: $2.2891 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02281279)

Source record
DIN 02281279: Act Fluconazole Raw flags: sec3=Y Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id ACV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.2891; ministry $2.2891 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02281279 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76692
Interchangeable products
Apo-Fluconazole · DIN 02237371 · $2.2891 Diflucan · DIN 00891819 · not recorded Fluconazole · DIN 02517418 · $2.2891 Fluconazole · DIN 02534894 · $2.2891 Mylan-Fluconazole · DIN 02245293 · $2.2891 PMS-Fluconazole · DIN 02245644 · $2.2891 Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: discontinued (December 20, 2024, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02281279
Shortage record checked October 6, 2026

Apo-Fluconazole · DIN 02237371 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Fluconazole · DIN 02237371 Manufacturer: Apotex Inc.; listing date 1999-09-15 Daily cost (source): $2.2891 Health Canada: Marketed since 2024-08-29 · brand APO-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Fluconazole: Formulary list price $2.29 per unit (the source does not state the unit; exact figure $2.2891). What the ministry pays, not the patient.

Ministry pays: $2.2891 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237371)

Source record
DIN 02237371: Apo-Fluconazole Raw flags: sec3=Y Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.2891; ministry $2.2891 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237371 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60694
Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891 Diflucan · DIN 00891819 · not recorded Fluconazole · DIN 02517418 · $2.2891 Fluconazole · DIN 02534894 · $2.2891 Mylan-Fluconazole · DIN 02245293 · $2.2891 PMS-Fluconazole · DIN 02245644 · $2.2891 Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: resolved shortage (ended January 21, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237371
Shortage record checked October 6, 2026

Fluconazole · DIN 02517418 · 100 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Fluconazole · DIN 02517418 Manufacturer: Sanis Health Inc.; listing date 2022-03-31 Daily cost (source): $2.2891 Health Canada: Marketed since 2022-01-14 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fluconazole: Formulary list price $2.29 per unit (the source does not state the unit; exact figure $2.2891). What the ministry pays, not the patient.

Ministry pays: $2.2891 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517418)

Source record
DIN 02517418: Fluconazole Raw flags: sec3=Y Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.2891; ministry $2.2891 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517418 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100681
Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891 Apo-Fluconazole · DIN 02237371 · $2.2891 Diflucan · DIN 00891819 · not recorded Fluconazole · DIN 02534894 · $2.2891 Mylan-Fluconazole · DIN 02245293 · $2.2891 PMS-Fluconazole · DIN 02245644 · $2.2891 Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: anticipated shortage (last updated October 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517418
Shortage record checked October 6, 2026

Fluconazole · DIN 02534894 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Fluconazole · DIN 02534894 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-12-29 Daily cost (source): $2.2891 Health Canada: Marketed since 2023-10-24 · brand FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fluconazole: Formulary list price $2.29 per unit (the source does not state the unit; exact figure $2.2891). What the ministry pays, not the patient.

Ministry pays: $2.2891 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02534894)

Source record
DIN 02534894: Fluconazole Raw flags: sec3=Y Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.2891; ministry $2.2891 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02534894 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102378
Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891 Apo-Fluconazole · DIN 02237371 · $2.2891 Diflucan · DIN 00891819 · not recorded Fluconazole · DIN 02517418 · $2.2891 Mylan-Fluconazole · DIN 02245293 · $2.2891 PMS-Fluconazole · DIN 02245644 · $2.2891 Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534894
Shortage record checked October 6, 2026

Mylan-Fluconazole · DIN 02245293 · 100 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mylan-Fluconazole · DIN 02245293 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2003-04-16 Daily cost (source): $2.2891 Health Canada: Marketed since 2009-12-17 · brand MYLAN-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Fluconazole: Formulary list price $2.29 per unit (the source does not state the unit; exact figure $2.2891). What the ministry pays, not the patient.

Ministry pays: $2.2891 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245293)

Source record
DIN 02245293: Mylan-Fluconazole Raw flags: sec3=Y Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id MYL Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.2891; ministry $2.2891 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245293 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69317
Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891 Apo-Fluconazole · DIN 02237371 · $2.2891 Diflucan · DIN 00891819 · not recorded Fluconazole · DIN 02517418 · $2.2891 Fluconazole · DIN 02534894 · $2.2891 PMS-Fluconazole · DIN 02245644 · $2.2891 Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: anticipated shortage (last updated September 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245293
Shortage record checked October 6, 2026

PMS-Fluconazole · DIN 02245644 · 100 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Fluconazole · DIN 02245644 Manufacturer: Pharmascience Inc.; listing date 2003-01-30 Daily cost (source): $2.2891 Health Canada: Marketed since 2002-06-05 · brand PMS-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 100 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Fluconazole: Formulary list price $2.29 per unit (the source does not state the unit; exact figure $2.2891). What the ministry pays, not the patient.

Ministry pays: $2.2891 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245644)

Source record
DIN 02245644: PMS-Fluconazole Raw flags: sec3=Y Item: 081204024; group id 9; item number 0012; lccId 00002; manufacturer id PMS Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.2891; ministry $2.2891 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245644 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69744
Interchangeable products
Act Fluconazole · DIN 02281279 · $2.2891 Apo-Fluconazole · DIN 02237371 · $2.2891 Diflucan · DIN 00891819 · not recorded Fluconazole · DIN 02517418 · $2.2891 Fluconazole · DIN 02534894 · $2.2891 Mylan-Fluconazole · DIN 02245293 · $2.2891 Teva-Fluconazole · DIN 02236979 · $2.2891
Shortage status: resolved shortage (ended September 9, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245644
Shortage record checked October 6, 2026

Apo-Fluconazole-150 · DIN 02241895 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Fluconazole-150 · DIN 02241895 Manufacturer: Apotex Inc.; listing date 2001-03-07 Health Canada: Marketed since 2011-03-02 · brand APO-FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Apotex inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Fluconazole-150: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02241895)

Source record
DIN 02241895: Apo-Fluconazole-150 Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id APX Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241895 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65565
Interchangeable products
Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: resolved shortage (ended February 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241895
Shortage record checked October 6, 2026

Bio-Fluconazole · DIN 02462168 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Fluconazole · DIN 02462168 Manufacturer: Biomed Pharma; listing date 2026-09-29 Health Canada: Marketed since 2019-09-20 · brand BIO-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Biomed pharma · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Bio-Fluconazole: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02462168)

Source record
DIN 02462168: Bio-Fluconazole Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id BMP Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02462168 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94989
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462168
Shortage record checked October 6, 2026

Diflucan-150 · DIN 02141442 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Diflucan-150 · DIN 02141442 Manufacturer: Pfizer Canada Inc.; listing date 1998-12-31 Health Canada: Marketed since 2019-07-25 · brand DIFLUCAN ONE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Pfizer canada ulc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02141442)

Source record
DIN 02141442: Diflucan-150 Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id PFI Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $15.6500; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02141442 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17789
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02141442
Shortage record checked October 6, 2026

Fluconazole-150 · DIN 02521229 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Fluconazole-150 · DIN 02521229 Manufacturer: Sanis Health Inc.; listing date 2022-07-29 Health Canada: Marketed since 2022-05-12 · brand FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Sanis health inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Fluconazole-150: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02521229)

Source record
DIN 02521229: Fluconazole-150 Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id SAI Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02521229 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101044
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02521229
Shortage record checked October 6, 2026

Jamp Fluconazole 150mg · DIN 02547864 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Fluconazole 150mg · DIN 02547864 Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30 Health Canada: Marketed since 2025-03-11 · brand JAMP FLUCONAZOLE 150 MG · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Fluconazole 150mg: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547864)

Source record
DIN 02547864: Jamp Fluconazole 150mg Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id JPC Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547864 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103678
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547864
Shortage record checked October 6, 2026

Mar-Fluconazole-150 · DIN 02428792 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Fluconazole-150 · DIN 02428792 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2017-01-31 Health Canada: Marketed since 2016-12-14 · brand MAR-FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Marcan pharmaceuticals inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Fluconazole-150: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02428792)

Source record
DIN 02428792: Mar-Fluconazole-150 Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id MAR Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02428792 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91325
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428792
Shortage record checked October 6, 2026

Priva-Fluconazole · DIN 02433702 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Priva-Fluconazole · DIN 02433702 Manufacturer: Pharmapar Inc.; listing date 2021-06-30 Health Canada: Marketed since 2025-01-17 · brand NRA-FLUCONAZOLE-150 · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Nora pharma inc · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Priva-Fluconazole: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02433702)

Source record
DIN 02433702: Priva-Fluconazole Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id PHP Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02433702 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91806
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: resolved shortage (ended August 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02433702
Shortage record checked October 6, 2026

Riva-Fluconazole · DIN 02255510 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Fluconazole · DIN 02255510 Manufacturer: Laboratoire Riva Inc.; listing date 2024-04-30 Health Canada: Marketed since 2014-11-01 · brand RIVA-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Laboratoire riva inc. · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Riva-Fluconazole: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02255510)

Source record
DIN 02255510: Riva-Fluconazole Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id RIA Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02255510 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74071
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Jamp-Fluconazole · DIN 02432471 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02255510
Shortage record checked October 6, 2026

Jamp-Fluconazole · DIN 02432471 · 150 mg · capsule

Limited Use, Reason for Use code 235 requiredDormant since August 3, 2026 · checked October 5, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 235 required
Write on scriptReason for Use code 235 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 235
Reason for Use code 235 For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day. Coverage limit: Repeats within a 25 day period will not be reimbursed. Coverage limit: LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Fluconazole · DIN 02432471 Manufacturer: Jamp Pharma Corporation; listing date 2015-03-31 Health Canada: Dormant since 2026-08-03 · brand JAMP-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Capsule · route Oral · ingredients FLUCONAZOLE 150 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Fluconazole: Formulary list price $3.94 per unit (the source does not state the unit; exact figure $3.9424). What the ministry pays, not the patient.

Ministry pays: $3.9424 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02432471)

Source record
DIN 02432471: Jamp-Fluconazole Raw flags: sec12=Y, sec3=Y Item: 840408048; group id 820; item number 2002; lccId 00116; manufacturer id JPC Source form: Cap; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.9424; ministry $3.9424 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02432471 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91671
Interchangeable products
Apo-Fluconazole-150 · DIN 02241895 · $3.9424 Bio-Fluconazole · DIN 02462168 · $3.9424 Diflucan-150 · DIN 02141442 · $3.9424 Fluconazole-150 · DIN 02521229 · $3.9424 Jamp Fluconazole 150mg · DIN 02547864 · $3.9424 Mar-Fluconazole-150 · DIN 02428792 · $3.9424 Priva-Fluconazole · DIN 02433702 · $3.9424 Riva-Fluconazole · DIN 02255510 · $3.9424
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02432471
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.

Teva-Fluconazole · DIN 02236978 · 50 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Fluconazole · DIN 02236978 Manufacturer: Teva Canada Limited; listing date 2003-04-16 Daily cost (source): $2.5808 Health Canada: Cancelled post market since 2025-07-30 · brand TEVA-FLUCONAZOLE · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Fluconazole: Formulary list price $1.29 per unit (the source does not state the unit; exact figure $1.2904). What the ministry pays, not the patient.

Ministry pays: $1.2904 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02236978)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02236978). DIN 02236978: Teva-Fluconazole Raw flags: dinStatus=E, sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: General benefit; DIN status E, meaning unconfirmed Source prices (unrounded): $1.2904; ministry $1.2904 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02236978 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60273
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Apo-Fluconazole · DIN 02237370 · $1.2904 Diflucan · DIN 00891800 · not recorded Fluconazole · DIN 02517396 · $1.2904 Fluconazole · DIN 02534886 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236978
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2025 — choose a marketed DIN from the same-category list.

Diflucan · DIN 00891800 · 50 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.Discontinued July 2, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-07-02 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Diflucan · DIN 00891800 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Daily cost (source): $2.5808 Health Canada: Cancelled post market since 2025-07-02 · brand DIFLUCAN · ATC J02AC01 FLUCONAZOLE · form Tablet · route Oral · ingredients FLUCONAZOLE 50 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Diflucan: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00891800)

Source record
DIN 00891800: Diflucan Raw flags: notABenefit=Y, sec3=Y Item: 081204023; group id 9; item number 0011; lccId 00002; manufacturer id PFI Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00891800 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10952
Interchangeable products
Act Fluconazole · DIN 02281260 · $1.2904 Apo-Fluconazole · DIN 02237370 · $1.2904 Fluconazole · DIN 02517396 · $1.2904 Fluconazole · DIN 02534886 · $1.2904 Mylan-Fluconazole · DIN 02245292 · $1.2904 PMS-Fluconazole · DIN 02245643 · $1.2904 Teva-Fluconazole · DIN 02236978 · $1.2904
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00891800
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 2, 2025 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J02A, J02AC): coverage varies; not interchangeable

  • Itraconazole (Sporanox): general benefit, limited Use 570, not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Posaconazole (Posanol): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Caspofungin (Cancidas): not a benefit

1 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): ITRACONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles

Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, KETOCONAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

KETOCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Cr

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Treatment DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the treatment of serious systemic candidal infections, including urinary tract infection, peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS). Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Prophylaxis DIFLUCAN is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. 1.1 Pediatrics (<18 years of age) Based on the data submitted and reviewed by Health Canada, the safety and efficacy of DIFLUCAN in pediatric patients ha… https://pdf.hres.ca/dpd_pm/00085459.PDF PM date: 2026-07-21 Source product: DIFLUCAN; DIN 02024152; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Act Fluconazole · DIN 02281260 Shortage status: discontinued (2024-12-20, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02281260

Check this DIN again

Apo-Fluconazole · DIN 02237370 Shortage status: shortage reported ended 2026-06-05 (report last updated 2026-06-05); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237370

Check this DIN again

PMS-Fluconazole · DIN 02245643 Shortage status: active shortage (reported 2026-09-25, estimated to end 2026-11-10, last updated 2026-09-28); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245643

Check this DIN again

Act Fluconazole · DIN 02281279 Shortage status: discontinued (2024-12-20, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02281279

Check this DIN again

Teva-Fluconazole · DIN 02236978 Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236978

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Diflucan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026